Printer Friendly

PE, Death Not Reduced With Early Vena Cava Filter Placement; Findings seen in severely injured patients with a contraindication to prophylactic anticoagulation.

THURSDAY, July 11, 2019 (HealthDay News) -- Early prophylactic placement of a vena cava filter compared with no placement of a filter after major trauma does not result in a reduced incidence of symptomatic pulmonary embolism or death at 90 days, according to a study published online July 7 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the International Society on Thrombosis and Haemostasis, held from July 6 to 10 in Melbourne, Australia.

Kwok M. Ho, Ph.D., from the University of Western Australia in Perth, and colleagues conducted a randomized trial involving 240 severely injured patients who had a contraindication to anticoagulant agents. Participants were randomly assigned to either have a vena cava filter placed within the first 72 hours of admission or not.

The researchers found that early placement of a vena cava filter did not result in a significantly lower incidence of symptomatic pulmonary embolism or death versus no filter placement (13.9 versus 14.4 percent; hazard ratio, 0.99; 95 percent confidence interval, 0.51 to 1.94; P = 0.98). Among the patients who did not receive prophylactic anticoagulation within seven days after injury (46 patients in the vena cava filter group and 34 in the control group), pulmonary embolism developed in none and in five (14.7 percent) patients, respectively.

"Our data suggest that there is no urgency to insert the filter in patients who can be treated with prophylactic anticoagulation within seven days after injury," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required) More Information

COPYRIGHT 2019 HealthDay
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Physician's Briefings
Geographic Code:8AUST
Date:Jul 11, 2019
Words:278
Previous Article:Rimegepant Shows Promise for Relief From Migraine Attacks; Increase seen in percentage of patients free from pain, from their most bothersome symptom...
Next Article:Exposure to 2009 pH1N1 Vaccine During Pregnancy Seems Safe; Exposure to pH1N1 influenza vaccine in utero not linked to most pediatric health outcomes.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters